3 cheap FTSE 100 dividend shares I’d buy now

These three dividend-paying FTSE 100 shares are valued attractively and have the potential to move higher, says Edward Sheldon, CFA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many FTSE 100 shares have performed well over the last few months. It’s fair to say that there’s a lot less value on offer today than there was in late March when the FTSE 100 was trading below 5,000 points.

That being said, there are still plenty of FTSE 100 shares that trade at very attractive valuations at present. Here’s a look at three cheap dividend-paying FTSE 100 stocks I’d be happy to buy today.

This FTSE 100 stock looks undervalued

The first cheap FTSE 100 stock I want to highlight is financial services giant Legal & General Group (LSE: LGEN). It currently trades on a forward-looking P/E ratio of just 7.4. At that valuation, I think the stock is significantly undervalued.

Earlier this month, analysts at Bank of America (BofA) Global Research upgraded LGEN to buy from neutral. They slapped a price target of 265p on the stock – 22% higher than the share price today.

BofA’s analysts also commented on LGEN’s bumper dividend yield, which currently stands at over 8%. “We think this is a particularly appealing proposition in a market starved of yield. Further, we think that the regulatory risk to the dividend is low,” they wrote to clients.

I fully agree with the BofA analysts’ view on Legal & General shares. I think the dividend yield here is very attractive. I’d buy this FTSE 100 share today.

Great buying opportunity

Another dividend-paying FTSE 100 share I’d be happy to buy today is Hikma Pharmaceuticals (LSE: HIK). It’s a fast-growing healthcare company that manufactures branded and non-branded generic medicines.

Hikma’s share price has fallen recently, despite the fact that the company issued a very encouraging trading update in April. The reason the shares have dropped? A major shareholder has sold a large amount of stock.

Personally, I think this share price weakness is a great buying opportunity. And I’m not the only one who sees an opportunity right now. Earlier this month, analysts at Morgan Stanley upgraded the stock to ‘overweight’ from ‘equal-weight’ and raised their price target from 2,200p to 2,600p. That price target is around 20% higher than the current share price.

Hikma shares currently trade on a forward-looking P/E ratio of 17.4. I think that’s quite cheap. The dividend yield on offer is about 1.6%.

A FTSE share with a 5% dividend yield

Finally, I also like the look of GlaxoSmithKline (LSE:GSK) right now.

I think GSK is a great stock to own in the current environment. For a start, I like the fact that the FTSE 100 company is one of the largest vaccine manufacturers in the world. This means it could play a key role in the fight against Covid-19. Just recently, the company advised that it was making a $163m investment in German biotech CureVac, to work together on a vaccine for the coronavirus.

Another thing I like about GSK is that it owns a whole portfolio of consumer healthcare brands that includes the likes of Voltaren, Panadol, and Fenbid. These kinds of trusted brands are attractive assets as they tend to generate consistent cash flows. That means GSK has defensive qualities.

GSK shares currently trade on a forward-looking P/E ratio of about 13.4. That’s an attractive valuation, in my view. The stock also offers a prospective dividend yield of about 5.1%. I’d be happy to buy this FTSE 100 champion today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in Legal & General Group and GlaxosmithKline. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What can Warren Buffett teach an investor with £1,000?

Although Warren Buffett’s a billionaire, his investing lessons can be applied to far more modest portfolios. Our writer explains some…

Read more »

Light bulb with growing tree.
Investing Articles

Down 43%, could the ITM share price start rising again in 2025?

After news of the latest sales deal being inked, our writer revisits the ITM share price and considers if the…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Is 2024’s biggest FTSE faller now the best share to buy for 2025?

Harvey Jones thought this FTSE 100 growth stock was the best share to buy for 2024, but was wrong. Yet…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

Legal & General has huge passive income potential with a forecast yield of almost 10% in 2025!

Harvey Jones got a fabulous rate of passive income from this top FTSE 100 dividend stock in 2024, and believes…

Read more »

Investing Articles

This stock market dip is my chance to buy cheap FTSE shares for 2025!

Harvey Jones was looking forward to a Santa Rally in December, but it looks like we're not going to get…

Read more »

Investing Articles

Analysts are saying the AstraZeneca share price looks cheap despite China turmoil

The AstraZeneca share price could be considerably undervalued according to analysts. Dr James Fox takes a closer look at the…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

1 FTSE 100 stock I expect to outperform in 2025

Can the integration of its big acquisition from 2022 finally lead Rentokil Initial to outperform the FTSE 100 next year?…

Read more »

Investing Articles

These are my top FTSE 250 REITs for earning passive income from dividends

The 90% profit distribution rule applied to REITs makes them an attractive option for dividend investors. Here are two of…

Read more »